DNLI (Denali Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DNLI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Peter Scott Chin | Chief Medical Officer | Sell | — | — |
| 2026-09-04 | Nancy Thornberry | Director | Sell | — | — |
| 2026-09-03 | Alexander O. Schuth | COFO and Secretary | Sell | — | — |
| 2026-08-14 | Ryan J. Watts | President and CEO | G | — | — |
| 2026-08-13 | Alexander O. Schuth | COFO and Secretary | Sell | — | — |
| 2026-06-05 | Jennifer E. Cook | Director | A | — | — |
| 2026-06-05 | David P Schenkein | Director | A | — | — |
| 2026-06-05 | Peter S Klein | Director | A | — | — |
| 2026-06-05 | Nancy Thornberry | Director | A | — | — |
| 2026-06-05 | Timothy Van Hauwermeiren | Director | A | — | — |
| 2026-06-05 | Steve E. Krognes | Director | A | — | — |
| 2026-06-05 | JAY T FLATLEY | Director | A | — | — |
| 2026-06-05 | Baker Bros. Advisors (GP) LLC | Director | A | — | — |
| 2026-01-08 | Alexander O. Schuth | COFO and Secretary | Sell | — | — |
| 2026-01-08 | Ryan J. Watts | President and CEO | Sell | — | — |
| 2026-01-05 | Ryan J. Watts | President and CEO | A | — | — |
| 2026-01-05 | Alexander O. Schuth | COFO and Secretary | A | — | — |
| 2025-12-15 | 667, L.P. | Director | Buy | — | — |
| 2025-11-06 | Timothy Van Hauwermeiren | Director | A | — | — |
| 2025-09-05 | Ryan J. Watts | President and CEO | G | — | — |
| 2025-08-14 | Carole Ho | Chief Medical Officer | Sell | — | — |
| 2025-08-14 | Alexander O. Schuth | COFO and Secretary | Sell | — | — |
| 2025-08-07 | Carole Ho | Chief Medical Officer | M | — | — |
| 2025-07-11 | Ryan J. Watts | President and CEO | MIXED | — | — |
| 2025-06-05 | Jennifer E. Cook | Director | A | — | — |
| 2025-06-05 | Peter S Klein | Director | A | — | — |
| 2025-06-05 | Steve E. Krognes | Director | A | — | — |
| 2025-06-05 | JAY T FLATLEY | Director | A | — | — |
| 2025-06-05 | David P Schenkein | Director | A | — | — |
| 2025-06-05 | Nancy Thornberry | Director | A | — | — |
| 2025-06-05 | JULIAN BAKER | Director | A | — | — |
| 2025-06-05 | Marc Tessier-Lavigne | Director | A | — | — |
| 2025-01-08 | Steve E. Krognes | Director | Sell | — | — |
| 2025-01-08 | Carole Ho | Chief Medical Officer | Sell | — | — |
| 2025-01-08 | Alexander O. Schuth | COFO and Secretary | Sell | — | — |
| 2025-01-08 | Ryan J. Watts | President and CEO | Sell | — | — |
| 2025-01-07 | Ryan J. Watts | President and CEO | A | — | — |
| 2025-01-07 | Carole Ho | Chief Medical Officer | A | — | — |
| 2025-01-07 | Alexander O. Schuth | COFO and Secretary | A | — | — |
| 2025-01-03 | VICKI L SATO | Director | Sell | — | — |
| 2025-01-03 | Steve E. Krognes | Director | Sell | — | — |
| 2024-12-31 | Alexander O. Schuth | COFO and Secretary | M | — | — |
| 2024-11-27 | Carole Ho | Chief Medical Officer | M | — | — |
| 2024-11-26 | Alexander O. Schuth | COFO and Secretary | M | — | — |
| 2024-11-13 | David P Schenkein | Director | MIXED | — | — |
| 2024-11-12 | VICKI L SATO | Director | Sell | — | — |
| 2024-11-12 | Alexander O. Schuth | COFO and Secretary | MIXED | — | — |
| 2024-11-05 | VICKI L SATO | Director | Sell | — | — |
| 2024-10-22 | Ryan J. Watts | President and CEO | MIXED | — | — |
| 2024-10-02 | Steve E. Krognes | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,644,881 | — |
| — | 10%+ Owner | 12,201,634 | — |
| — | 10%+ Owner | 11,068,749 | — |
| — | 10%+ Owner | 10,668,749 | — |
| — | Director | 9,681,181 | — |
| — | 10%+ Owner | 8,918,749 | — |
| — | Director | 3,422,366 | — |
| — | Director | 3,415,958 | — |
| — | President and CEO | 2,417,217 | — |
| — | Director | 1,965,424 | — |
| — | — | 1,815,536 | — |
| — | 10%+ Owner | 953,035 | — |
| — | 10%+ Owner | 953,035 | — |
| — | Director | 819,999 | — |
| — | COFO and Secretary | 802,744 | — |
| — | 10%+ Owner | 514,151 | — |
| — | Director | 358,941 | — |
| — | Chief Medical Officer | 242,391 | — |
| — | Chief Medical Officer | 204,538 | — |
| — | Director | 107,976 | — |
| — | 10%+ Owner | 100,102 | — |
| — | Director | 52,897 | — |
| — | Director | 33,941 | — |
| — | Director | 32,483 | — |
| — | — | 31,969 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DNLI quote page; the site-wide leaderboard is on the insider transactions hub.